The use is described of both (i) [1R-[1.alpha.(Z),2.beta.,3.beta.,5.alpha.]]-(+)-7-[5-[[(1,1'-biphenyl)-4-y l]methoxy]-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid or a physiologically acceptable salt or solvate thereof and (ii) a thromboxane synthase inhibitor, either separately or in combination in the therapy or prophylaxis of occlusive vascular diseases in humans. Pharmaceutical compositions containing both (i) and (ii) are also described.
Prolonged parenteral release of a bioactive somatotropin at desirably effective levels can be achieved using novel compositions in which the somatotropin is present in a biocompatible oil in an unusually high proportion such as at least about 10% by weight. Also disclosed are certain metal-associated somatotropins that are useful for prolonged parenteral release of such somatotropins.
Prolonged parenteral release of a bioactive polypeptide at desirably effective levels can be achieved using novel compositions in which the polypeptide is present in a biocompatible oil in an unusually high proportion such as at least about 10% by weight. Also disclosed are certain metal-associated somatotropins that are useful for prolonged parenteral release of such somatotropins.
Prolonged parenteral release of a bioactive polypeptide at desirably effective levels can be achieved using novel compositions in which the polypeptide is present in a biocompatible oil in an unusually high proportion such as at least about 10% by weight. Also disclosed are certain metal-associated somatotropins that are useful for prolonged parenteral release of such somatotropins.
